
HCA Healthcare, Inc.
NYSE•HCA
CEO: Mr. Samuel N. Hazen
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 2011-03-10
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Contact Information
Market Cap
$113.77B
P/E (TTM)
17.8
16
Dividend Yield
0.6%
52W High
$520.00
52W Low
$289.98
52W Range
Rank23Top 6.9%
6.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$19.16B+9.57%
4-Quarter Trend
EPS
-$10.54-313.36%
4-Quarter Trend
FCF
$3.13B+34.60%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Month Revenue Growth Revenues reached $56.087B USD, marking a 7.2% increase over prior nine months period ending September 30, 2025.
Net Income Improvement Net income attributable to HCA grew 13.5% to $4.906B USD for the nine months, driving diluted EPS to $20.23 USD.
Strong Operating Cash Flow Cash provided by operations totaled $10.277B USD, significantly up from $7.955B USD last year for the nine months.
Risk Factors
Regulatory Reimbursement Uncertainty Potential Medicare reimbursement cuts up to 4% in early 2026 loom due to Pay-As-You-Go Act sequestration requirements.
Widening Stockholder Deficit Retained deficit widened to $(5.020)B USD as capital returns, including $7.509B in repurchases, exceeded cumulative earnings.
Uninsured Care Cost Increase Estimated cost of total uncompensated care for nine months reached $3.359B USD, slightly up from $3.220B USD in 2024.
Outlook
Capital Expenditure Projections Planned capital expenditures are projected around $5.0B USD for the full year 2025, financed by internal funds and borrowing.
Debt Refinancing Capacity Management intends to utilize $8.0B senior unsecured credit facility capacity to refinance short-term commercial paper borrowings.
Policy Impact Resiliency Management is developing resiliency plans to offset potential financial impacts from OBBBA legislation and evolving health policy changes.
Peer Comparison
Revenue (TTM)
CVS$394.08B
MCK$387.09B
CI$268.13B
Gross Margin (Latest Quarter)
VRTX86.5%
SNY74.1%
GSK73.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MDT | $129.25B | 27.1 | 9.8% | 31.9% |
| SNY | $117.63B | 11.1 | 12.4% | 16.8% |
| VRTX | $114.10B | 30.9 | 19.6% | 7.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.6%
Moderate Growth
4Q Net Income CAGR
5.2%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Jan 23, 2026
EPS:$7.39
|Revenue:$19.66B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $19.16B+9.6%|EPS: $-10.54-313.4%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 4, 2025|Revenue: $18.61B+6.4%|EPS: $6.91+23.4%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 1, 2025|Revenue: $18.32B+5.7%|EPS: $6.52+7.9%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 14, 2025|Revenue: $70.60B+8.7%|EPS: $22.27+15.7%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $17.49B+7.9%|EPS: $4.94+24.1%MeetForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 29, 2024|Revenue: $17.49B+10.3%|EPS: $5.60+28.7%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $17.34B+11.2%|EPS: $6.04+22.8%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 16, 2024|Revenue: $64.97B+7.9%|EPS: $19.24-1.0%Beat